Swine Fever Vaccine: The Quest to Curb the Spread of African Swine Fever

 

Swine Fever Vaccine

Origins and History of African Swine Fever

African swine fever (ASF) is a severe hemorrhagic disease affecting pigs that was first described in Kenya in the early 1920s. Since then, it has spread throughout sub-Saharan Africa and parts of Europe. The disease is caused by ASF virus, which is acquired naturally by pig populations through contact with infected wild boars or soft ticks of the genus Ornithodoros. While non-pathogenic in wild boars and ticks, the virus can cause mortality rates of nearly 100% in domestic pigs.

Over the decades, ASF has caused severe production losses worldwide, threatening food security and livelihoods in many farming communities heavily dependent on pig rearing. Significant outbreaks occurred in Portugal during the 1950s-1960s, Spain in the 1970s, and Russia and neighboring countries from 2007 onwards. The last decade has seen unprecedented spread, with the Swine Fever Vaccine now present across much of Eastern Europe, Central Asia, the Pacific and East Asia, including China. Given increasing globalization and trade, there is growing risk of further international disease spread.

Development of Vaccines and Challenges

Due to the economic impact of ASF, intensive research has aimed to develop effective vaccines to help control the disease. However, ASF virus presents unique challenges. It does not grow in cell culture, hampering traditional vaccine approaches. The virus also has a complex structure, with about 20 different proteins serving important roles in virulence and immune evasion. This genetic diversity poses barriers to vaccine development approaches targeting specific proteins.

Despite these hurdles, experimental live-attenuated and inactivated vaccines have shown promise. Effective protection was demonstrated in some trials against less virulent virus strains. However, safety and efficacy remain inconsistent, particularly against more virulent strains currently circulating. Another constraint has been the lack of a reliable serological test to differentiate infected from vaccinated pigs (“DIVA” test), an essential tool for surveillance and trade. Without an effective DIVA test, vaccinated pigs cannot be exported due to the risk of undetected infection.

Continued Vaccine Development in China

China faces immense pressure to control ASF within its borders, the world’s largest pork producer and consumer. Annual pork output exceeds 50 million metric tons, accounting for over half of global production. But ASF emerged in 2018 and has since spread nationwide, infecting over 1 million pigs. Industry losses total billions of dollars annually. To curb the crisis, China is accelerating vaccine development through projects spanning multiple research institutes and companies.

Promising swine fever vaccine candidates utilize various technological platforms, including live-attenuated, inactivated, viral-vectored, subunit and nucleic acid-based approaches. Safety and efficacy are being evaluated through experimental challenge studies. Particular focus targets obtaining DIVA capability to eventually allow vaccination while still permitting pork exports. Challenges persist, but Chinese scientists express optimism that an effective licensed vaccine may become available within 3-5 years. International cooperation on research and regulatory matters aims to expedite progress. A successful Chinese vaccine could revolutionize global ASF control.

Regulatory Pathways and Considerations

Should future vaccine trials demonstrate adequate protection, the next stage involves regulatory approval and licensed production/use. For any new animal vaccine, developers must demonstrate safety for the vaccinated animal as well as unvaccinated animals that come into contact, other species, and humans handling the product. They must also prove efficacy through controlled challenge trials and define parameters such as minimum protective dose levels, administration routes, duration of immunity and antigen stability.

Regulators will then assess manufacturing processes and quality controls to ensure reproducible high standards are maintained during commercial-scale production. Post-licensure pharmacovigilance will continuously monitor vaccine performance and safety in field conditions. For an ASF vaccine, obtaining the support of trading partners for an effective DIVA strategy remains a high priority to permit vaccination without trade restrictions. Overall, the regulatory pathway is often lengthy and complex but aims to only license vaccines that meet rigorous standards of safety, quality and performance.

African swine fever poses a critical and growing threat to global food security as its geographic range continues expanding. Developing an effective vaccine would significantly aid control programs through containment of outbreaks and protecting vulnerable populations. While major hurdles have hindered progress to-date, ongoing research especially in China holds promise. Continued international collaboration on vaccine development, regulatory approval pathways and implementing effective DIVA testing can help overcome current constraints. Success would save billions of dollars while curbing animal welfare impacts of disease spread. The quest is challenging but achieving a licensed swine fever vaccine could prove transformational for pig farmers worldwide.

 

Gets More Insights on, Swine Fever Vaccine

 

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)